Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Allergen-Specific Immunotherapy With Liposome Containing CpG-ODN in Murine Model of Asthma Relies on MyD88 Signaling in Dendritic Cells

Full text
Author(s):
Alberca-Custodio, Ricardo Wesley [1] ; Faustino, Lucas D. [2] ; Gomes, Eliane [1] ; Nunes, Fernanda Peixoto Barbosa [1] ; de Siqueira, Mirian Krystel [1] ; Labrada, Alexis [3] ; Almeida, Rafael Ribeiro [1] ; Camara, Niels Olsen Saraiva [1] ; da Fonseca, Denise Morais [1] ; Russo, Momtchilo [1]
Total Authors: 10
Affiliation:
[1] Univ Sao Paulo, Inst Biomed Sci, Dept Immunol, Sao Paulo - Brazil
[2] Harvard Med Sch, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Massachusetts Gen Hosp, Boston, MA 02115 - USA
[3] Natl Ctr Bioproducts BIOCEN, Dept Allergens, Havana - Cuba
Total Affiliations: 3
Document type: Journal article
Source: FRONTIERS IN IMMUNOLOGY; v. 11, APR 23 2020.
Web of Science Citations: 0
Abstract

Changing the immune responses to allergens is the cornerstone of allergen immunotherapy. Allergen-specific immunotherapy that consists of repeated administration of increasing doses of allergen extract is potentially curative. The major inconveniences of allergen-specific immunotherapy include failure to modify immune responses, long-term treatment leading to non-compliance and the potential for developing life-threating anaphylaxis. Here we investigated the effect of a novel liposomal formulation carrying low dose of allergen combined with CpG-ODN, a synthetic TLR9 agonist, on established allergic lung inflammation. We found that challenge with allergen (OVA) encapsulated in cationic liposome induced significantly less severe cutaneous anaphylactic reaction. Notably, short-term treatment (three doses) with a liposomal formulation containing co-encapsulated allergen plus CpG-ODN, but not allergen or CpG-ODN alone, reversed an established allergic lung inflammation and provided long-term protection. This liposomal formulation was also effective against allergens derived from Blomia tropicalis mite extract. The attenuation of allergic inflammation was not associated with increased numbers of Foxp3-positive or IL-10-producing regulatory T cells or with increased levels of IFN-gamma in the lungs. Instead, the anti-allergic effect of the liposomal formulation was dependent of the innate immune signal transduction generated in CD11c-positive putative dendritic cells expressing MyD88 molecule. Therefore, we highlight the pivotal role of dendritic cells in mediating the attenuation of established allergic lung inflammation following immunotherapy with a liposomal formulation containing allergen plus CpG-ODN. (AU)

FAPESP's process: 15/25364-0 - Impact of infection-induced immunological scarring on the long-term host metabolic homeostasis
Grantee:Denise Morais da Fonseca
Support type: Research Grants - Young Investigators Grants
FAPESP's process: 15/16728-9 - Immunotherapy of experimental asthma by agonists of toll-like receptors
Grantee:Fernanda Peixoto Barbosa Nunes
Support type: Scholarships in Brazil - Post-Doctorate
FAPESP's process: 14/19906-2 - Transcriptional profile of t follicular helper (Tfh) cells and b cell isotype switching induced by type 1 or type 2 adjuvants
Grantee:Momtchilo Russo
Support type: Regular Research Grants
FAPESP's process: 13/24694-1 - Immunotherapy of experimental asthma by agonists of toll-like receptors, infection or tolerance
Grantee:Momtchilo Russo
Support type: Research Projects - Thematic Grants
FAPESP's process: 17/05264-7 - Cell metabolism, microbiota and immune system: new paradigms in renal diseases physiopathology
Grantee:Niels Olsen Saraiva Câmara
Support type: Research Projects - Thematic Grants
FAPESP's process: 16/16602-8 - Immunotherapy in experimental asthma by CpG
Grantee:Ricardo Wesley Alberca Custódio
Support type: Scholarships in Brazil - Doctorate